The University of Michigan offers the state's only accredited heart failure disease management program, with medical and surgical care, heart-assisting technology and comprehensive rehabilitation programs.
Medical Services related to Keith David Aaronson MD
Heart transplant is one of a number of options for severe heart disease. It's not for everyone, and should not be considered unless all other viable treatment options have been unsuccessful. At the University of Michigan Heart Transplant Program, our closely integrated team of cardiac transplant surgeons and transplant cardiologists are able to treat and implant donor hearts in the sickest of patients because of our high volume, vast experience and active research program.
Hereditary Hemorrhagic Telangiectasia (HHT) is a genetic disorder that affects about one in 5000 people and commonly causes nosebleeds, with more frequent nosebleeds typically starting after about age 12. Patients with HHT have a tendency to form blood vessels that are abnormal, fragile, and bleed more easily.
VADs (ventricular assist devices) are mechanical devices that help your heart pump blood to the rest of your body when other methods don't relieve heart failure symptoms. These devices are most commonly used to support the left side of the heart (LVADs) and may be used to support the right side of the heart (RVADs) as well. University of Michigan is home to one of the largest VAD programs in the country, and is one of only a few institutions worldwide that has access to many investigational and FDA-approved mechanical circulatory support devices.
The VAD Program at the University of Michigan offers one of the nation's most comprehensive programs in the area of treatment for severe chronic or acute heart failure. This goes beyond conventional treatment, giving patients access to a broad variety of state-of-the-art options of circulatory support devices and skilled post-implantation care.